EA202090184A3 - Пептидные композиции и способы использования - Google Patents
Пептидные композиции и способы использованияInfo
- Publication number
- EA202090184A3 EA202090184A3 EA202090184A EA202090184A EA202090184A3 EA 202090184 A3 EA202090184 A3 EA 202090184A3 EA 202090184 A EA202090184 A EA 202090184A EA 202090184 A EA202090184 A EA 202090184A EA 202090184 A3 EA202090184 A3 EA 202090184A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- peptide compositions
- photoreceptor
- fas
- trail
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 108091008695 photoreceptors Proteins 0.000 abstract 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 abstract 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 abstract 1
- 108700012411 TNFSF10 Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155711P | 2015-05-01 | 2015-05-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA202090184A2 EA202090184A2 (ru) | 2020-05-31 |
| EA202090184A3 true EA202090184A3 (ru) | 2020-07-31 |
Family
ID=57217771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792399A EA035293B1 (ru) | 2015-05-01 | 2016-04-29 | Пептидные композиции и способы использования |
| EA202090184A EA202090184A3 (ru) | 2015-05-01 | 2016-04-29 | Пептидные композиции и способы использования |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792399A EA035293B1 (ru) | 2015-05-01 | 2016-04-29 | Пептидные композиции и способы использования |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10508134B2 (enExample) |
| EP (3) | EP3288379B1 (enExample) |
| JP (2) | JP6884755B2 (enExample) |
| KR (2) | KR102652804B1 (enExample) |
| CN (2) | CN113651873B (enExample) |
| AU (1) | AU2016258837B2 (enExample) |
| CA (1) | CA2984154A1 (enExample) |
| CY (1) | CY1124911T1 (enExample) |
| DK (1) | DK3288379T3 (enExample) |
| EA (2) | EA035293B1 (enExample) |
| ES (1) | ES2906173T3 (enExample) |
| HR (1) | HRP20220138T1 (enExample) |
| HU (1) | HUE057883T2 (enExample) |
| LT (1) | LT3288379T (enExample) |
| MX (1) | MX387317B (enExample) |
| PL (1) | PL3288379T3 (enExample) |
| PT (1) | PT3288379T (enExample) |
| RS (1) | RS62866B1 (enExample) |
| SI (1) | SI3288379T1 (enExample) |
| SM (1) | SMT202200069T1 (enExample) |
| WO (1) | WO2016178993A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6884755B2 (ja) | 2015-05-01 | 2021-06-09 | オーエヌエル セラピューティクス，インコーポレーテッド | ペプチド組成物および使用方法 |
| EP3768301A4 (en) * | 2018-03-20 | 2022-06-08 | ONL Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR FAS INHIBITION |
| AU2019288296B2 (en) * | 2018-06-19 | 2022-11-24 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| KR20220118499A (ko) * | 2019-12-18 | 2022-08-25 | 셀라 테라퓨틱스, 엘엘씨 | 신경영양제, 세포자멸 신호전달 단편 억제제(FAS) 또는 FAS 리간드(FASL) 억제제, 종양 괴사 인자-α(TNF-α) 또는 TNF 수용체 억제제, 미토콘드리아 펩티드, 올리고뉴클레오티드, 케모카인 억제제 또는 시스테인-아스파틱 프로테아제 억제제를 포함하는 약물 전달 시스템 |
| US20240285724A1 (en) * | 2021-06-15 | 2024-08-29 | Onl Therapeutics, Inc. | Methods and compositions for treating ocular disorders and diseases |
| WO2023287794A2 (en) * | 2021-07-13 | 2023-01-19 | Onl Therapeutics, Inc. | Methods and compositions for improving visual function in ocular diseases and disorders |
| WO2023129766A1 (en) * | 2021-12-27 | 2023-07-06 | Onl Therapeutics, Inc. | Sfasl for inhibiting rpe cell death and associated disorders |
| WO2024031024A1 (en) * | 2022-08-05 | 2024-02-08 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
| WO2024031022A2 (en) * | 2022-08-05 | 2024-02-08 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
| WO2024220669A1 (en) * | 2023-04-19 | 2024-10-24 | Onl Therapeutics, Inc. | Methods and compositions for treating rnfl thinning |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5532123A (en) * | 1990-07-11 | 1996-07-02 | New York University | Receptor-type phosphotyrosine phosphatase-γ |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| JP3187201B2 (ja) * | 1992-05-14 | 2001-07-11 | 三共株式会社 | Ｃ末端にプロリンアミドを有するペプチドの製法 |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| JP3460863B2 (ja) | 1993-09-17 | 2003-10-27 | 三菱電機株式会社 | 半導体装置の製造方法 |
| US5714353A (en) | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| US5527928A (en) | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
| US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
| US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5711964A (en) | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
| US6001962A (en) | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
| US7091047B2 (en) * | 1997-05-23 | 2006-08-15 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity |
| US6363020B1 (en) | 1999-12-06 | 2002-03-26 | Virage Logic Corp. | Architecture with multi-instance redundancy implementation |
| US6480428B2 (en) | 2000-12-19 | 2002-11-12 | Winbond Electronics Corporation | Redundant circuit for memory device |
| EP1730186A2 (en) * | 2004-03-31 | 2006-12-13 | Xencor, Inc. | Bmp-7 variants with improved properties |
| EP1737483A2 (en) | 2004-04-23 | 2007-01-03 | University of Pittsburgh of the Commonwealth System of Higher Education | Cell death modulation via antagonists of fasl and fas activation |
| ES2322200T3 (es) * | 2005-05-10 | 2009-06-17 | Alcon, Inc. | Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos. |
| US8067433B2 (en) * | 2005-11-09 | 2011-11-29 | Zalicus Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
| US20080280834A1 (en) | 2005-12-01 | 2008-11-13 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds and methods for inhibiting apoptosis |
| EP2222696A1 (en) * | 2007-12-21 | 2010-09-01 | Stryker Corporation | Bmp mutants with decreased susceptibility to noggin |
| AU2010221341B2 (en) | 2009-03-03 | 2013-12-19 | The Regents Of The University Of Michigan | Methods of inhibiting photoreceptor apoptosis |
| US20120101046A1 (en) * | 2009-03-30 | 2012-04-26 | Santen Pharmaceutical Co., Ltd. | Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide |
| EP2462128B1 (en) * | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| EP2678433B1 (en) | 2011-02-22 | 2017-05-03 | California Institute of Technology | Delivery of proteins using adeno-associated virus (aav) vectors |
| TW201542231A (zh) * | 2011-06-06 | 2015-11-16 | Kineta One Llc | 以ｓｈｋ為主之醫藥組合物及其製備方法及用途 |
| CA2861543C (en) * | 2012-01-18 | 2022-05-31 | Governing Council Of The University Of Toronto | Novel peptides and methods and uses thereof for preventing retinal disorders |
| WO2013191352A1 (en) * | 2012-06-21 | 2013-12-27 | Hanall Biopharma Co., Ltd. | New uses of modified human tumor necrosis factor receptor-1 polypeptide |
| CA2890238A1 (en) * | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| EP3254106A4 (en) | 2015-02-05 | 2018-10-03 | Immunarray USA, Inc. | Methods and compositions for diagnosing brain injury or neurodegeneration |
| JP6884755B2 (ja) | 2015-05-01 | 2021-06-09 | オーエヌエル セラピューティクス，インコーポレーテッド | ペプチド組成物および使用方法 |
| US20190201500A1 (en) | 2015-05-01 | 2019-07-04 | Onl Therapeutics, Inc. | Compositions and methods of fas inhibition |
| CN110177577A (zh) | 2016-07-05 | 2019-08-27 | 马萨诸塞大学 | Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法 |
| EP3642229A1 (en) | 2017-06-21 | 2020-04-29 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
| EP3768301A4 (en) | 2018-03-20 | 2022-06-08 | ONL Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR FAS INHIBITION |
| AU2019288296B2 (en) | 2018-06-19 | 2022-11-24 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
-
2016
- 2016-04-29 JP JP2018508624A patent/JP6884755B2/ja active Active
- 2016-04-29 EP EP16789830.3A patent/EP3288379B1/en active Active
- 2016-04-29 EA EA201792399A patent/EA035293B1/ru unknown
- 2016-04-29 SI SI201631458T patent/SI3288379T1/sl unknown
- 2016-04-29 CA CA2984154A patent/CA2984154A1/en active Pending
- 2016-04-29 MX MX2017014075A patent/MX387317B/es unknown
- 2016-04-29 ES ES16789830T patent/ES2906173T3/es active Active
- 2016-04-29 HR HRP20220138TT patent/HRP20220138T1/hr unknown
- 2016-04-29 LT LTEPPCT/US2016/030098T patent/LT3288379T/lt unknown
- 2016-04-29 PL PL16789830T patent/PL3288379T3/pl unknown
- 2016-04-29 WO PCT/US2016/030098 patent/WO2016178993A1/en not_active Ceased
- 2016-04-29 EP EP21200594.6A patent/EP3997981A1/en not_active Withdrawn
- 2016-04-29 CN CN202110665678.1A patent/CN113651873B/zh active Active
- 2016-04-29 KR KR1020177034366A patent/KR102652804B1/ko active Active
- 2016-04-29 US US15/570,948 patent/US10508134B2/en active Active
- 2016-04-29 SM SM20220069T patent/SMT202200069T1/it unknown
- 2016-04-29 KR KR1020247010090A patent/KR20240046280A/ko not_active Ceased
- 2016-04-29 RS RS20220095A patent/RS62866B1/sr unknown
- 2016-04-29 HU HUE16789830A patent/HUE057883T2/hu unknown
- 2016-04-29 CN CN201680038258.8A patent/CN107708416B/zh active Active
- 2016-04-29 PT PT167898303T patent/PT3288379T/pt unknown
- 2016-04-29 DK DK16789830.3T patent/DK3288379T3/da active
- 2016-04-29 AU AU2016258837A patent/AU2016258837B2/en active Active
- 2016-04-29 EP EP25186051.6A patent/EP4623925A2/en active Pending
- 2016-04-29 EA EA202090184A patent/EA202090184A3/ru unknown
-
2019
- 2019-11-04 US US16/673,513 patent/US10829518B2/en active Active
-
2020
- 2020-10-06 US US17/064,495 patent/US11597749B2/en active Active
-
2021
- 2021-05-12 JP JP2021080927A patent/JP2021120400A/ja active Pending
-
2022
- 2022-02-02 CY CY20221100088T patent/CY1124911T1/el unknown
-
2023
- 2023-01-24 US US18/159,021 patent/US12258425B2/en active Active
-
2025
- 2025-02-14 US US19/054,490 patent/US20250346631A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124911T1 (el) | Συνθεσεις πεπτιδιων και μεθοδοι χρησης | |
| CL2018001587A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| BR112016025819A2 (pt) | vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico | |
| EA201591599A1 (ru) | Ингибиторы ido | |
| EA201690152A1 (ru) | Ингибиторы ido | |
| EA201690306A1 (ru) | Ингибиторы ido | |
| EA201591823A1 (ru) | Ингибиторы ido | |
| MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| EA201790922A1 (ru) | Ингибиторы бромодомена | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| MX393803B (es) | Derivados de amida como bloqueadores de nav1.7 y nav1.8 | |
| IL272601A (en) | Pharmaceutical compositions for the treatment of ophthalmic conditions | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| EA201991377A1 (ru) | Композиции универсальной вакцины против гриппа | |
| EA201792262A1 (ru) | Пироглутамат вортиоксетина | |
| MX2016000448A (es) | Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido. | |
| MX2021000542A (es) | Apirasas solubilizadas, metodos y usos. | |
| EA201790893A1 (ru) | Способы лечения офтальмологических расстройств | |
| EA202091567A1 (ru) | Химерные белки мти | |
| EA202090971A1 (ru) | Способы применения и композиции, содержащие дулаглутид | |
| EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
| HUE061877T2 (hu) | Ciklosporin-analógok gyógyszerkészítményei | |
| MX383460B (es) | Derivados peptidicos novedosos y sus usos. | |
| EA202191758A1 (ru) | Пептиды для лечения и профилактики диабета и связанных с ним заболеваний | |
| EA201791456A1 (ru) | Пептиды-антагонисты cgrp |